|Specialty||Psychiatry, narcology, addiction medicine|
Barbiturate dependence develops with regular use of barbiturates. This in turn may lead to a need for increasing doses of the drug to get the original desired pharmacological or therapeutic effect. Barbiturate use can lead to both addiction and physical dependence, and as such they have a high potential for excess or non-medical use, however, it does not affect all users. Management of barbiturate dependence involves considering the affected person's age, comorbidity and the pharmacological pathways of barbiturates.
Psychological addiction to barbiturates can develop quickly. The patients will then have a strong desire to take any barbiturate-like drug. The chronic use of barbiturates leads to moderate degradation of the personality with narrowing of interests, passivity and loss of volition. The somatic signs include hypomimia, problems articulating, weakening of reflexes, and ataxia.
The GABAA receptor, one of barbiturates' main sites of action, is thought to play a pivotal role in the development of tolerance to and dependence on barbiturates, as well as the euphoric "high" that results from their use. The mechanism by which barbiturate tolerance develops is believed to be different from that of ethanol or benzodiazepines, even though these drugs have been shown to exhibit cross-tolerance with each other and poly drug administration of barbiturates and alcohol used to be common.
The management of a physical dependence on barbiturates is stabilisation on the long-acting barbiturate phenobarbital followed by a gradual titration down of dose. People who use barbiturates tend to prefer rapid-acting barbiturates (amobarbital, pentobarbital, secobarbital) rather than long-acting barbiturates (barbital, phenobarbital). The slowly eliminated phenobarbital lessens the severity of the withdrawal syndrome and reduces the chances of serious barbiturate withdrawal effects such as seizures. A cold turkey withdrawal can in some cases lead to death. Antipsychotics are not recommended for barbiturate withdrawal (or other CNS depressant withdrawal states) especially clozapine, olanzapine or low potency phenothiazines e.g. chlorpromazine as they lower the seizure threshold and can worsen withdrawal effects; if used extreme caution is required. The withdrawal symptoms after ending barbiturate consumption are quite severe and last from 4 to 7 days.
- Zapantis A, Leung S (September 2005). "Tolerance and withdrawal issues with sedation". Crit Care Nurs Clin North Am. 17 (3): 211–23. doi:10.1016/j.ccell.2005.04.011. PMID 16115529.
- Takehiko Ito; Toshihito Suzuki; Susan E. Wellman; Ing Kang Ho (June 1996). "Pharmacology of barbiturate tolerance/dependence: GABAA receptors and molecular aspects". Life Sciences. 59 (3): 169–95. doi:10.1016/0024-3205(96)00199-3. PMID 8699929.
- Santos C, Olmedo RE (2017). "Sedative-Hypnotic Drug Withdrawal Syndrome: Recognition And Treatment". Emerg Med Pract. 19 (3): 1–20. PMID 28186869.
- Jüri Saarma "Kliiniline psühhiaatria". Tallinn, 1980. P. 139.
- Allan AM, Zhang X, Baier LD (August 1992). "Barbiturate tolerance: effects on GABA-operated chloride channel function". Brain Res. 588 (2): 255–60. doi:10.1016/0006-8993(92)91583-Z. PMID 1382810. S2CID 33787357.
- Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants By Donald G. Barceloux. P. 469
- Tyrer, Peter; Silk, Kenneth R., eds. (24 January 2008). Cambridge Textbook of Effective Treatments in Psychiatry (1st ed.). Cambridge University Press. p. 406. ISBN 978-0-521-84228-0.
- Ebadi, Manuchair (23 October 2007). "Alphabetical presentation of drugs". Desk Reference for Clinical Pharmacology (2nd ed.). USA: CRC Press. p. 512. ISBN 978-1-4200-4743-1.